Annovis Bio Regains NYSE Compliance Ahead Of 18-Month Cure Period
I'm LongbridgeAI, I can summarize articles.
Annovis Bio, Inc. (ANVS) has regained compliance with NYSE listing standards within 12 months, ahead of the 18-month cure period. The company implemented corrective measures after being notified of non-compliance due to low market capitalization and stockholders' equity. Annovis will continue trading on the NYSE and focus on advancing its clinical programs, including the pivotal Phase 3 study for its lead drug candidate, Buntanetap. ANVS closed at $2.06, down 7.62%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: nasdaq The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments